***** Back in early May 2020, Dr Patterson, on "Te
Post# of 148286
(Total Views: 420)
Posted On: 02/14/2021 11:58:08 AM
***** Back in early May 2020, Dr Patterson, on "Ted Talks" had told
the world of the powerful potential of Leronlimab, a "cure" for CV-19!
***** Back in early May 2020, the FDA knew of the pristine safety and strong
efficacy of Leronlimab against the growing covid-19 pandemic.
***** "May be effective" and is known to be safe?????
A powerful example of Leronlimab's eIND successes is below.
So in May 2020, what did the FDA do?
They initiated their stringent deadly slow, ridiculously ignorant protocol, which almost a year later, has prevented Leronlimab from turning the pandemic around, resulting in hundreds of thousand of deaths in the USA. Is it evil? Some folks have called this behavior a genocide.
How will history view the FDA?
Harish Seethamraju, M.D., an organ transplant specialist and a member of the department of medicine at Montefiore and Einstein, researched leronlimab early in the pandemic, and realized its potential for treating his transplant patients who had COVID-19. He then obtained “compassionate use” permission from the Food and Drug Administration so that he and his colleagues could use leronlimab on 10 severely ill COVID-19 patients, six of them transplant patients from various organ transplant programs.
“By calming the overactive immune systems of these patients, leronlimab halted the inflammation and blood clotting that are so damaging to the lungs, liver and kidneys of severely ill COVID-19 patients,” said Dr. Seethamraju. All 10 patients had extremely high blood levels of CCL5, which are inflammatory molecules known as cytokines. This is why the extreme inflammatory response is known as the “cytokine storm.” Leronlimab interfered with those CCL5 molecules, preventing them from directing immune cells to swarm into and inflame the lungs and other organs.
On May 5th, a study describing promising results for those 10 severely ill patients was made public on the website, MedRxiv, a resource especially useful during the COVID-19 pandemic to make research quickly available to the scientific community. Co-authored by Dr. Seethamraju, the study reported that five of the 10 patients treated with leronlimab survived; the study also described the drug as “a novel approach” to resolving unchecked inflammation.
the world of the powerful potential of Leronlimab, a "cure" for CV-19!
***** Back in early May 2020, the FDA knew of the pristine safety and strong
efficacy of Leronlimab against the growing covid-19 pandemic.
***** "May be effective" and is known to be safe?????
A powerful example of Leronlimab's eIND successes is below.
So in May 2020, what did the FDA do?
They initiated their stringent deadly slow, ridiculously ignorant protocol, which almost a year later, has prevented Leronlimab from turning the pandemic around, resulting in hundreds of thousand of deaths in the USA. Is it evil? Some folks have called this behavior a genocide.
How will history view the FDA?
Harish Seethamraju, M.D., an organ transplant specialist and a member of the department of medicine at Montefiore and Einstein, researched leronlimab early in the pandemic, and realized its potential for treating his transplant patients who had COVID-19. He then obtained “compassionate use” permission from the Food and Drug Administration so that he and his colleagues could use leronlimab on 10 severely ill COVID-19 patients, six of them transplant patients from various organ transplant programs.
“By calming the overactive immune systems of these patients, leronlimab halted the inflammation and blood clotting that are so damaging to the lungs, liver and kidneys of severely ill COVID-19 patients,” said Dr. Seethamraju. All 10 patients had extremely high blood levels of CCL5, which are inflammatory molecules known as cytokines. This is why the extreme inflammatory response is known as the “cytokine storm.” Leronlimab interfered with those CCL5 molecules, preventing them from directing immune cells to swarm into and inflame the lungs and other organs.
On May 5th, a study describing promising results for those 10 severely ill patients was made public on the website, MedRxiv, a resource especially useful during the COVID-19 pandemic to make research quickly available to the scientific community. Co-authored by Dr. Seethamraju, the study reported that five of the 10 patients treated with leronlimab survived; the study also described the drug as “a novel approach” to resolving unchecked inflammation.
(6)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼